Galderma Group AG - Company Profile

Powered by

All the sales intelligence you need on Galderma Group AG in one solution.

$ $295
Register your interest Learn more
  • Save hours of research time with a comprehensive
    Sales Intelligence Solution.

  • Understand how Galderma Group AG fits into your total
    addressable market and Ideal Customer Profile.

  • Gain competitive edge with triggers that tell you
    when and how to engage with Galderma Group AG.

Back to companies

Galderma Group AG: Overview

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward

Select Item

Related keylists

Galderma Group AG (Galderma) provides science-based solutions for skin health. The company’s activities involve the development and distribution of skincare products and medical solutions. Its product portfolio includes prescription drugs, consumer skincare products and aesthetic solutions. The company’s major brands include Azzalure, Restylane, Sculptra, Cetaphil, and Alastin. Galderma serves its products to a wide range of skin health needs, for the treatment of maintaining healthy skin and rejuvenating aging skin. It is distributed through a network of healthcare professionals and retailers, reaching consumers across various industries. The company has a global presence, operating in over 90 countries. Galderma is headquartered in Lausanne, Lake Geneva, Switzerland.

 Gain a 360-degree view of Galderma Group AG and make more informed decisions for your business Gain a 360-degree view of Galderma Group AG and make more informed decisions for your business Learn more
Headquarters Switzerland
Address Zaehlerweg 10, Zug, 6300
Website www.galderma.com
Telephone 41 58 4558592
No of Employees 10
Industry Pharmaceuticals and Healthcare
Ticker Symbol & Exchange GALD (SWF)
Revenue (2024) $5.2B 18% (2024 vs 2023)
EPS XYZ
Net Income (2024) XYZ 164.9% (2024 vs 2023)
Market Cap* $51.6B
Net Profit Margin (2024) XYZ 124.6% (2024 vs 2023)
* As of and is in US$
View Galderma Group AG financials
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Learn more

Galderma Group AG premium industry data and analytics

340+

Clinical Trials

Determine Galderma Group AG go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

100+

Catalyst Calendar

Proactively evaluate Galderma Group AG’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

80+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Galderma Group AG’s relevant decision makers and contact details.

50+

Marketed Drugs

Understand Galderma Group AG’s commercialized product portfolio to stay one step ahead of the market.

18+

Pipeline Drugs

Identify which of Galderma Group AG’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

17+

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

10+

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

2

IT Services Contracts

Improve competitive bidding with insights into all publicly disclosed IT services contracts for Galderma Group AG (including IT outsourcing, business process outsourcing, systems integration & consulting and more).

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on Galderma Group AG’s likely spend across technology areas enabling you to understand the digital strategy.

Products and Services

Products Brands
Categories: Epiduo
Prescription Differin
Consumer Mirvaso
XYZ XYZ
XYZ XYZ
XYZ XYZ
Understand Galderma Group AG portfolio and identify potential areas for collaboration Understand Galderma Group AG portfolio and identify potential areas for collaboration Learn more

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2025 Plans/Strategy In December, the company announced its plans to sell its 10% stake to L’Oréal, a cosmetics company.
2024 Regulatory Approval In December, the company's monoclonal antibody, Nemluvio (nemolizumab) secured approval from the US Food and Drug Administration for individuals aged 12 years and over with moderate-to-severe atopic dermatitis.
2024 Stake Sale In August, the company sold its 10% stake held by Sunshine SwissCo, Abu Dhabi Investment Authority, and Auba Investment to L'Oreal, a multinational personal care company.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Learn more
Image for loader

Competitor Comparison

Key Parameters Galderma Group AG Bausch Health Companies Inc Almirall Hermal GmbH Aesthetic Medical International Holdings Group Ltd Merz Aesthetics
Headquarters Switzerland Canada Germany China United States of America
City Zug Laval Reinbek Shenzhen Raleigh
State/Province - Quebec Schleswig-Holstein Guangdong North Carolina
No. of Employees 10 20,300 299 - -
Entity Type Public Public Private Public Private
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Learn more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Learn more
Executives
Name Position Board Since Age
Thomas Ebeling Chairman Executive Board 2022 67
Flemming Ornskov MD Chief Executive Officer; Director Executive Board 2019 68
Luigi La Corte Chief Financial Officer Senior Management 2026 -
Allison Pinkham Chief Human Resources Officer Senior Management 2022 51
Sherilyn McCoy Vice Chairman Executive Board - 68
Non Dignissim Eros Proin vel Convallis 2026 XY
Non Dignissim Eros Proin vel Convallis 2026 XY
Non Dignissim Eros Proin vel Convallis 2026 XY
Gain insight into Galderma Group AG key executives to enhance your sales strategy Gain insight into Galderma Group AG key executives to enhance your sales strategy Learn more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Why are you leaving?